Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carmen Amanda Gay

Physician Assistant Austin, TX Physician Assistant

NPI 1467416248 CMS profile 10498097

6618 Sitio Del Rio Blvd Ste B101, Austin, TX 78730

Open in the dashboard

General payments

$12,666

706 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carmen Amanda Gay of Austin, TX is reported in the CMS Open Payments database as having received $12,666 across 706 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,954 98
2024 General $2,510 127
2023 General $2,837 156
2022 General $2,445 143
2021 General $2,919 182

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carmen Amanda Gay
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Carmen Amanda Gay were reported at $1,954. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Carmen Amanda Gay Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,919 $132 $37–$438 $132
2022 $2,445 $155 $48–$522 $149
2023 $2,837 $167 $52–$557 $160
2024 $2,510 $178 $55–$600 $164
2025 $1,954 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,571 141 payments
  2. Novo Nordisk Inc $1,520 86 payments
  3. AstraZeneca Pharmaceuticals LP $1,028 53 payments
  4. GlaxoSmithKline, LLC. $825 54 payments
  5. Lilly USA, LLC $765 47 payments
  6. Pfizer Inc. $635 32 payments
  7. Bausch Health US, LLC $558 28 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $510 36 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $475 32 payments
  10. Collegium Pharmaceutical, Inc. $402 18 payments
  11. Other $3,379 179 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,646 703 payments
  2. Education $19 3 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,341 76 payments
  2. RYBELSUS $1,306 74 payments
  3. VRAYLAR $916 54 payments
  4. UBRELVY $859 44 payments
  5. TRELEGY ELLIPTA $812 53 payments
  6. SYNTHROID $684 36 payments
  7. NURTEC ODT Pain $627 31 payments
  8. APLENZIN $558 28 payments
  9. FARXIGA $554 27 payments
  10. NURTEC ODT Primary Care $541 35 payments
  11. Other $7,862 439 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

1,411

Median for Physician Assistant: 241

Drug cost

$162,933

Median for Physician Assistant: $4,110

Branded share of claims

19.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 31 $38,858
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 38 $28,913
Farxiga Dapagliflozin Propanediol Brand 23 $23,667
Trulicity Dulaglutide Brand 16 $21,091
Mounjaro Tirzepatide Brand 13 $17,252
Icosapent Ethyl Generic 13 $6,393
Breo Ellipta Fluticasone/Vilanterol Brand 12 $4,481
Synthroid Levothyroxine Sodium Brand 16 $2,027
Azelastine Hcl Generic 63 $1,798
Valacyclovir Valacyclovir Hcl Brand 31 $1,548

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $232
$232 23 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $208
$208 38 —
UBRELVY
  • AbbVie, Inc. $200
$200 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $192
$192 — —
NURTEC ODT
  • PFIZER INC. $153
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

706 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record